To in-line with the ICH guideline Q1A(R2), Itraconazole was subjected to acidic ,basic and oxidative stress . Drug was stable in all the conditions except oxidation stress. Separated the two oxidative degradation products, by using gradient elution, C8 column on preparative HPLC and structural elucidation was performed by using 1D & 2D NMR spectroscopic studies and mass analysis. Those are recognized as 1-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl) methoxy) phenyl)-4-(4-(1-(sec-butyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl)piperazine 1,4-dioxide(DP-1), 1-(4-((2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(4-(1-(sec-butyl)-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl)phenyl) piperazine 1-oxide (DP-2).These degradents are innovative impurities which are found first time in this product. Moreover, the degradation mechanism from Itraconazole to DP-1 and DP-2 was also proposed.
INTRODUCTION
Itraconazole (ITZ) is a broad-spectrum, synthetic triazole antifungal agent. Chemically it is (4- Forced degradation studies of a drug candidate is an important part of drug discovery and drug development stages [1] [2] [3] and are widely used to predict drug stability problems and identify degradation products or potential impurities. The advantage of stress testing under different conditions is that it provides more comprehensive information on the degradation pathway of the drug. When a drug degrades, it may result in the loss of drug activity and degradation products may elicit possible adverse reactions. The international conference on harmonization guidelines Q1A (R2) require that all degradation products formed during the forced degradation of a drug under various stress conditions should be characterized. 4 Therefore, degradation product and impurity profiling is one of the most important areas of modern pharmaceutical analysis. Stress studies are conducted to create degradation /debasement items in greater quantities as they are framed in low proportions (0.1-0.5%, w/w) during storage. 5 and still, after all that, a considerable lot of the occasions, it is fairly hard to disconnect these contaminations from the focused on blend because of their low sums and subject them to unearthly investigations for basic data.
TWO NOVEL DEGRADANT PRODUCTS IN ITRACONAZOLE Santhosh Guduru et al.
A few analytical and bioanalytical methods have been reported in the literature for the determination of ITZ. It includes estimation of ITZ alone or ITZ and it's in vivo metabolites in biological matrices. [6] [7] [8] [9] [10] [11] [12] A comprehensive study has been undertaken to isolate and characterize these impurities by prep HPLC and spectroscopic techniques. This research article describes the separation, identification, isolation and characterization of two impurities that are present in the range of 6.95% and 9.49% by peak area in the bulk drug of Itraconazole. 
EXPERIMENTAL

High-Resolution Mass Spectrometry and MS/MS
HRMS study was conducted by using waters micro mass Q-TOF instrument in the positive mode with Mass lynx software and ESI as an ion source. The Leucine encephalin (m/z: 555.62268 Da) was chosen as an internal standard to have accurate results. SHIMADZU SIL HTC 5500 Qtrap was taken for MS/MS and water c18 column with dimensions 250X3.0mm of 5.0µ particle size was used for chromatographic technique with a flow rate of 0.5 mL/min, also used the gradient program as mobile phase A: 0.1% formic acid(Aq); mobile phase B: Acetonitrile:
Nuclear Magnetic Resonance Spectroscopy The 1 H, 13 C NMR and 2D NMR spectra of oxidative degradation impurities were recorded in DMSO-d6 solvent on Bruker 500 MHz Avance -III HD NMR spectrometer equipped with BBO Probe. The 1 H and 13 C chemical shifts are reported on δ scale in ppm, relative to tetra methyl silane (TMS) as an internal standard. The spectra were set to δ 0.00 ppm in 1 H NMR (TMS) and δ 39.50 ppm in 13 C NMR (DMSOd6).
Hydrolytic stress methods Oxidation degradation
The drug was subjected to stress as per ICH guideline Q1A (R2) to identify the potential degradants those could be generated during the storage. Oxidation degradation studies were carried out as per the guidelines of ICH. 200 mg of standard drug was suspended in 10 ml of 5% H2O2 and stirred at room temperature for 24 h to study oxidation degradation and stirring was continued till 48 h to achieve sufficient degradation.
RESULTS AND DISCUSSION
Even though the required impurities were formed in 24 hrs time under stirring of media, it was continued up to 48hrs to get the more quantity of the impurity. 1 mL of the above degradation solution was taken into methanol followed by diluted with mobile phase and subjected to LC-MS system and observed two degradant impurities (Fig.-1) . Furthermore, no degradations were found in other instances and oxidation degradation solution was sent/diverted for isolation/purification TWO NOVEL DEGRADANT PRODUCTS IN ITRACONAZOLE Santhosh Guduru et al. 
Isolation of Peroxide Degradation Products
Lyophilization /Purification procedure was adopted to isolate the two degradants from the corresponding fractions and named as DP-1 & DP-2, later structural elucidation was performed by using 1D & 2D NMR spectroscopic studies and HRMS analysis. The identified impurity structures were verified against the Literature search and found to be new products.Structures of Itraconazole and degradation products DP-1 and DP-2 were shown in (Fig.-2) .
MS/MS Analysis
After conducting the mass spectrometric analysis on Itraconazole and its isolated degradation products the Reasonable fragmentation pathways of Itraconazole drug substance and its degradation products(DP-1,DP-2) were captured in (Fig.-3) , (Fig.-4) and (Fig.-5) 
Structure Elucidation of DP-1
The HRMS showed a protonated molecular ion peak at m/z 737.2383 [M+H] + corresponding to molecular formula C35H39Cl2N8O6. This mass data indicating that 32 mass units higher than drug(ITRACONAZOLE) mass 704.The 1 H NMR spectrum revealed that the DP-1 had 24 aliphatic protons, 14 aromatic protons .The 13 C NMR spectrum showed 13 aliphatics carbon and 22 aromatic carbons. 1H, 13C chemical shift values for DP1 was assigned by using 1H,13C, HSQC and HMBC Experiments. The assignments of DP-1 are shown in Table- (Fig.-2) .
Structure Elucidation of DP-2
The High-resolution MS data revels that the molecular ion peak at m/z value 721.2430 [M+H] + is attributed to a molecular formula of C35H39Cl2N8O5. This mass data indicating that 16 mass units higher than drug(ITRACONAZOLE) mass 704. (Fig.-2) for DP-2. A plausible mechanism for the formation of degradation products DP-1 and DP-2 from itraconazole drug substance during oxidation was shown in (Fig.-6) . 
CONCLUSION
When the drug was subjected to oxidation, two novel degradant products were observed. These two degradant products structures were confirmed by HRMS and NMR data wise. These products so far not published in any journal as per our literature search.
